Fortrea Fortifies Leadership to Target Early-Phase Clinical Market

DURHAM, N.C. – February 17, 2026 – Fortrea has made a significant strategic move to bolster its executive ranks, signaling a sharpened focus on the highly competitive early-phase clinical development sector. The global contract research organization (CRO) announced it has dedicated Dr. Oren Cohen, a veteran medical leader, to his role as Chief Medical Officer (CMO) and has appointed Dr. Scott Dove, an experienced operations executive, as the new President of its Clinical Pharmacology Services (CPS) division.

The restructuring, which places both executives on Fortrea's Executive Committee, effectively splits a dual role previously held by Dr. Cohen. This allows him to concentrate entirely on overarching medical strategy, scientific leadership, and governance, while Dr. Dove takes the helm of the company's global early-stage clinical trial operations. The move is a clear indicator of Fortrea's ambition to deepen its scientific partnerships and enhance its operational prowess as it continues to forge its identity following its spin-off from Labcorp in mid-2023.

A Strategic Push in a High-Stakes Arena

This executive expansion is more than a simple personnel shuffle; it represents a calculated maneuver within the fierce CRO landscape. The early clinical development market, encompassing Phase I and clinical pharmacology studies, is a critical battleground where biopharmaceutical clients make foundational decisions about the future of their assets. Fortrea's key competitors, including industry giants IQVIA and PPD (part of Thermo Fisher Scientific), have long-established, extensive networks and deep expertise in this area.

By creating two distinct, high-level leadership positions from one, Fortrea is investing in specialized focus. The company aims to provide clients with both elite-level scientific and medical counsel from the very beginning of the development process, and simultaneously, best-in-class operational execution of those early-phase trials.

“The addition of Scott to the Fortrea team while Oren becomes fully dedicated to the medical and scientific aspects of development is a win for clients,” said Anshul Thakral, CEO of Fortrea, in the company's announcement. Thakral noted that Dr. Cohen will now engage earlier and more deeply in scientific dialogues with clients, while Dr. Dove's operational track record is expected to strengthen the clinical pharmacology offering. This dual-pronged approach is designed to enhance both strategic value and executional certainty for Fortrea's partners.

The Power of Specialized Expertise

The backgrounds of the two executives underscore the strategic intent behind the new structure.

Dr. Oren Cohen's career is marked by deep scientific and medical leadership. Before his tenure at Fortrea and its predecessor Labcorp Drug Development, he served as Chief Medical and Scientific Officer at Quintiles (now IQVIA), where he oversaw its early clinical development unit. His academic and research credentials are just as formidable, including an MD from Duke University and a fellowship at the National Institute of Allergy and Infectious Diseases (NIAID) under Dr. Anthony Fauci. His transition to a dedicated CMO role elevates the position, allowing him to apply this extensive experience across Fortrea's entire portfolio, focusing on complex development challenges, scientific integrity, and patient safety. This move reflects a broader industry trend recognizing the need for a strong, independent medical voice at the highest level of CRO leadership to navigate increasingly complex trial designs and regulatory environments.

In contrast, Dr. Scott Dove brings over 25 years of robust operational and drug development experience. His more than a decade at PPD, where he led early development services, gives him direct experience running a major CPS division for a top-tier competitor. His more recent role as Chief Operating Officer at the oncology-focused biotech Aravive provided him with invaluable client-side perspective on R&D operations. This background positions him perfectly to lead Fortrea’s global network of clinical research units, focusing on efficiency, quality, and the seamless execution of early-phase studies. His appointment is a direct injection of proven operational leadership into a vital part of the business.

Building a Post-Spin-Off Powerhouse

These appointments are a key part of the larger transformation underway at Fortrea under CEO Anshul Thakral, who took the helm in August 2025. Since its launch as an independent entity, Fortrea has been working to establish its own strategic direction and operational rhythm. The company's financial performance has been a focus for investors; while it posted higher-than-expected revenue of $701.3 million in its most recent quarter, it also recorded a net loss and a decline in adjusted EBITDA.

However, a strong book-to-bill ratio of 1.13x and a growing backlog of $7.6 billion suggest healthy demand for its services. Analyst sentiment has been improving, with several upgrades in late 2025 and early 2026, and forecasts anticipate a return to profitability this year. The company is navigating a significant debt load but is executing a plan focused on profitable growth and cost management.

Against this backdrop, the investment in top-tier leadership for the CPS division is a forward-looking move. It demonstrates a commitment to strengthening core service offerings that are critical for long-term growth and market share. By ensuring its early-phase clinical engine is run by a dedicated operational expert and overseen by a top-flight medical strategist, Fortrea is building a leadership structure designed to win business and deliver results, thereby solidifying its position as a formidable, independent player in the global CRO market. The move is a tangible step in its journey to become a transformative force from pipeline to patient.